Nkarta to host April 25 conference call to discuss Phase 1 data for NKX101 and NKX019

Nkarta, Inc.

Conference call scheduled for April 25, 2022 at 8:00 a.m. ET to review preliminary clinical data.
NKX101 and NKX019 are engineered NK cell therapy candidates in ongoing Phase 1 trials.
Leading investigators from the two clinical trials will join management for the discussion.
Webcast and accompanying slides available on Nkarta’s website with replay for ~4 weeks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.